It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
L-arginine (L-ARG)-nitric oxide (NO)–cGMP (cyclic guanosine monophosphate) cycle has been determined in various studies to be associated with epilepsy. Tadalafil is a potent inhibitor of phosphodiesterase 5 (PDE5) and increases the level of cGMP. Methylene blue (MB) is a lipophilic agent regulating intracellular electron flow as well as increasing the mitochondrial effectiveness. It also decreases cGMP levels by directly inhibiting guanylate cyclase.The aim of the present study was to evaluate the effects of MB and tadalafil on pentylenetetrazol-induced seizures. MB and tadalafil were administered 30 min prior to PTZ (70 mg/kg, i.p.) injection and the dose-response ratio was determined. Racine's Convulsion Scale and first myoclonic jerk (FMJ) onset time was used to evaluate seizures. Besides, drugs were administered 30 min prior to pentylenetetrazol (35 mg/kg, i.p.) injection and EEG was recorded from cortex and the spike wave discharges was determined in EEG. Plasma cGMP levels were measured in all groups. 5 and 10 mg/kg MB decreased Racine convulsion stage, increased FMJ onset time and decreased cGMP levels when compared with saline. 10 mg/kg tadalafil increased cGMP levels and Racine convulsion stage but decreased FMJ onset time compared with saline. Spike wave discharges were decreased in 5 and 10 mg/kg MB groups and increased in 10 mg/ kg tadalafil group when compared with saline group.The proconvulsant properties of all the agents may be taken into consideration, especially when prescribing PDE5 inhibitors.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer